Further re Directorate Change

RNS Number : 2526D

Genedrive PLC

02 March 2022

 

genedrive plc

("genedrive" or the "Company")

Further re Directorate Change

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, confirms that Matthew Fowler, the Group's Chief Financial Officer, will be leaving the Company and stepping down from the Board on 19 April 2022.  This follows the announcement on 16 November 2021 that Matthew Fowler intended to stand down after five years in the role, in order to take up a position as Chief Financial Officer of musicMagpie plc.

The Company will make a futher announcement in due course with regards to recruitment of a new Chief Financial Officer.

For further details please contact:

genedrive plc
David Budd: CEO		[phone]
Peel Hunt LLP (Nominated Adviser and Joint Broker)		[phone]
James Steel
finnCap (Joint Broker)		[phone]
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media Relations & In vestor Relations)	[phone] or [e-mail]
Paul McManus / Anna Dunphy		[phone] / [phone]

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, a h igh throughput SARS-CoV-2 assay and a test to help in the prevention of hearing loss caused by certain antibiotics in neonates.  The Company recently released a point of care test for Covid-19.

 

END

 

 

FURBKDBQPBKDBNK